ENFLURANE

Details

Stereochemistry	RACEMIC
Molecular Formula	C3H2ClF5O
Molecular Weight	184.492
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC(F)OC(F)(F)C(F)Cl

InChI

InChIKey=JPGQOUSTVILISH-UHFFFAOYSA-N

InChI=1S/C3H2ClF5O/c4-1(5)3(8,9)10-2(6)7/h1-2H

HIDE SMILES / InChI

Molecular Formula	C3H2ClF5O
Molecular Weight	184.492
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017087s048lbl.pdf

Enflurane (2-chloro-1,1,2,-trifluoroethyl-difluoromethyl ether) is a halogenated ether structural isomer of isoflurane. Developed by Ross Terrell in 1963, it was first used clinically in 1966. It was increasingly used for inhalational anesthesia during the 1970s and 1980s but is no longer in common use. Clinically, enflurane produces a dose-related depression of myocardial contractility with an associated decrease in myocardial oxygen consumption. Between 2% and 5% of the inhaled dose is oxidized in the liver, producing fluoride ions and difluoromethoxy-difluoroacetic acid. This is significantly higher than the metabolism of its structural isomer isoflurane. The exact mechanism of the action of general anesthetics has not been delineated. Enflurane acts as a positive allosteric modulator of the GABAA, glycine, and 5-HT3 receptors, and as a negative allosteric modulator of the AMPA, kainate, and NMDA receptors, as well as of nicotinic acetylcholine receptors.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Glycine receptor 13 Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644	Positive Allosteric Modulator 179
Glutamate receptor ionotropic AMPA 41 Target ID: CHEMBL2096670 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790	Negative Allosteric Modulator 42
Glutamate [NMDA] receptor 125 Target ID: CHEMBL2094124 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790	Negative Allosteric Modulator 42
Glutamate receptor ionotropic kainate 24 Target ID: CHEMBL2109241 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7681790	Negative Allosteric Modulator 42
GABA-A receptor; anion channel 202 Target ID: CHEMBL2094107 Sources: https://www.ncbi.nlm.nih.gov/pubmed/16973644	Positive Allosteric Modulator 179

Conditions

Condition	Modality	Targets	Highest Phase	Product
Pain 614 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/017087s048lbl.pdf	Primary		Approved 8429	ETHRANE Approved Use INDICATIONS AND USAGE. ĒTHRANE (enflurane, USP) may be used for induction and maintenance of general anesthesia. Enflurane may be used to provide analgesia for vaginal delivery. Low concentrations of enflurane (see DOSAGE AND ADMINISTRATION) may also be used to supplement other general anesthetic agents during delivery by Cesarean section. Higher concentrations of enflurane may produce uterine relaxation and an increase in uterine bleeding. Launch Date 1972

C_max

Value	Dose	Co-administered	Analyte	Population
15 μg/mL REVIEW https://www.springer.com/gp/book/9783540117193	2 % single, respiratory dose: 2 % route of administration: Respiratory experiment type: SINGLE co-administered:		ENFLURANE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
60 min REVIEW https://www.springer.com/gp/book/9783540117193	2 % single, respiratory dose: 2 % route of administration: Respiratory experiment type: SINGLE co-administered:		ENFLURANE plasma	Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
4 % single, respiratory Dose: 4 % Route: respiratory Route: single Dose: 4 % Sources: https://pubmed.ncbi.nlm.nih.gov/1200833	unhealthy, 25 years n = 1 Health Status: unhealthy Condition: cholecystitis Age Group: 25 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1200833	Disc. AE: Malignant hyperthermia... AEs leading to discontinuation/dose reduction: Malignant hyperthermia Sources: https://pubmed.ncbi.nlm.nih.gov/1200833

AEs

AE	Significance	Dose	Population
Malignant hyperthermia	Disc. AE	4 % single, respiratory Dose: 4 % Route: respiratory Route: single Dose: 4 % Sources: https://pubmed.ncbi.nlm.nih.gov/1200833	unhealthy, 25 years n = 1 Health Status: unhealthy Condition: cholecystitis Age Group: 25 years Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1200833

Overview

CYP3A4	CYP2C9	CYP2D6	hERG

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	CYP2E1 667

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP2E1 667	substrate 3367 Sources: https://pubmed.ncbi.nlm.nih.gov/8162670/	yes

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4792	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4792
ChemicalBook	CB1361418	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB1361418
MolPort	MolPort-001-773-112	https://www.molport.com/shop/molecule-link/MolPort-001-773-112
eMolecules	890951	https://www.emolecules.com/cgi-bin/more?vid=890951

PubMed

Title	Date	PubMed
The relationship of brain catecholamine levels to enflurane requirements among three strains of mice with different anesthetic sensitivities.	2001	14566529
[Effects of non-depolarizing muscle relaxants on the duration of mivacurium].	2001	11510427
Volatile general anesthetics reveal a neurobiological role for the white and brown genes of Drosophila melanogaster.	2001 Dec	11745669
Gender-related plasma levels of progesterone, interleukin-8 and interleukin-10 during and after cardiopulmonary bypass in infants and children.	2001 Dec	11737923
The future of inhalation anaesthesia. Die Zukunft der Inhalationsanasthesie.	2001 Jun	11475628
Lack of degradation of sevoflurane by a new carbon dioxide absorbent in humans.	2001 Jun	11465591
[Role of nitric oxide (NO) in the mechanism of anesthetic action].	2001 May-Jun	11510365
[Alcohol-xenobiotic interactions. Role of cytochrome P450 2E1].	2001 Nov	11762131
Flumazenil improves cognitive and neuromotor emergence and attenuates shivering after halothane-, enflurane- and isoflurane-based anesthesia.	2001 Nov	11698314
Carbon monoxide production from desflurane, enflurane, halothane, isoflurane, and sevoflurane with dry soda lime.	2001 Nov	11684991
Double-masked randomized trial comparing alternate combinations of intraoperative anesthesia and postoperative analgesia in abdominal aortic surgery.	2001 Nov	11684971
Interaction of volatile anesthetics with human Kv channels in relation to clinical concentrations.	2001 Oct	11605938
Sensitive determination of four general anaesthetics in human whole blood by capillary gas chromatography with cryogenic oven trapping.	2001 Oct 5	11589453
[Effects of enflurane on respiratory neurons of the pre-Bötzinger complex in medullary slices of neonatal rats].	2001 Sep	11593718
Myristate, a 14-carbon fatty acid, effectively reverses anesthesia.	2002 Aug	12151949
Effects of halothane and enflurane anesthesia on sympathetic beta-adrenoreceptor-mediated pulmonary vasodilation in chronically instrumented dogs.	2002 Aug	12151940
PKQuest: measurement of intestinal absorption and first pass metabolism - application to human ethanol pharmacokinetics.	2002 Aug 15	12182761
PKQuest: a general physiologically based pharmacokinetic model. Introduction and application to propranolol.	2002 Aug 15	12182760
An unusual case of driving under the influence of enflurane.	2002 Aug 28	12175964
The effects of some porphyrinogenic drugs on the brain cholinergic system.	2002 Feb	11929041
Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma.	2002 Feb 1	11875717
[A study of the feasibility and efficacy of fetal surgical closure of spontaneous cleft lip in CL/fraser mice].	2002 Jan	11889828
Predictive performance of a physiological model for enflurane closed-circuit anaesthesia: effects of continuous cardiac output measurements and age-related solubility data.	2002 Jan	11883377
Fresh gas flow is not the only determinant of volatile agent consumption: a multi-centre study of low-flow anaesthesia.	2002 Jan	11881883
The inhibitory effects of anesthetics and ethanol on substance P receptors expressed in Xenopus oocytes.	2002 Jan	11772805
Comparison of Amsorb, sodalime, and Baralyme degradation of volatile anesthetics and formation of carbon monoxide and compound a in swine in vivo.	2002 Jan	11753018
Increased lymphatic lipid transport in genetically diabetic obese rats.	2002 Jan	11751159
[Inhalation anesthesia with halogen-containing anesthetics in children].	2002 Jan-Feb	11998385
Degrees of aversion shown by rats and mice to different concentrations of inhalational anaesthetics.	2002 Jun 29	12120924
Respiratory response to skin incision during anaesthesia with infusions of propofol and alfentanil.	2002 May	12067001
A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.	2002 May 20	12085211
Experimental investigation of the behavior of gas phase simulated moving beds.	2002 May 31	12113344
Mice with glycine receptor subunit mutations are both sensitive and resistant to volatile anesthetics.	2002 Sep	12198041
Comparison of the effects of neuroleptanesthesia and enflurane or sevoflurane anesthesia on neuromuscular blockade by rocuronium.	2003	12903925
Correlation between 5-fluorouracil metabolism and treatment response in two variants of C26 murine colon carcinoma.	2003 Aug 18	12915890
[Calibration of a room air gas monitor with certified reference gases].	2003 Dec	14691626
Fluoride metabolism in smokers and non-smokers following enflurane anaesthesia.	2003 Dec	14633748
General anesthetic actions in vivo strongly attenuated by a point mutation in the GABA(A) receptor beta3 subunit.	2003 Feb	12475885
Anaesthetic agents in adult day case surgery.	2003 Jan	12553381
Halogenated anesthetics reduce interleukin-1beta-induced cytokine secretion by rat alveolar type II cells in primary culture.	2003 Jan	12502982
Enflurane as an internal standard in monitoring halogenated volatile anaesthetics by headspace gas chromatography-mass spectrometry.	2003 Jan 24	12580493
A new method of inhalation anesthesia with nasopharyngeal insufflation in rat experiment.	2003 Jul	14562613
Cold and mechanical allodynia in both hindpaws and tail following thoracic spinal cord hemisection in rats: time courses and their correlates.	2003 Jun 12	12770696
Halogenated inhalational anaesthetics.	2003 Mar	12751547
Volatile anesthetics regulate pulmonary vascular tension through different potassium channel subtypes in isolated rabbit lungs.	2003 Mar	12620956
[Drug-induced seizures].	2003 Mar 31	12715674
Interaction between artificial membranes and enflurane, a general volatile anesthetic: DPPC-enflurane interaction.	2003 May	12719242
Enflurane decreases glutamate neurotransmission to spinal cord motor neurons by both pre- and postsynaptic actions.	2003 May	12707133
An isothermal titration calorimetry study on the binding of four volatile general anesthetics to the hydrophobic core of a four-alpha-helix bundle protein.	2003 Nov	14581228
Volatile anaesthetics induce biochemical alterations in the heme pathway in a B-lymphocyte cell line established from hepatoerythropoietic porphyria patients (LBHEP) and in mice inoculated with LBHEP cells.	2004 Feb	14643887

Patents

Sample Use Guides

In Vivo Use Guide

Surgical levels of anesthesia may be maintained with 0.5 to 3.0% enflurane. Maintenance concentrations should not exceed 3.0%. If added relaxation is required, supplemental doses of muscle relaxants may be used. Ventilation to maintain the tension of carbon dioxide in arterial blood in the 35 to 45 mm Hg range is preferred. Hyperventilation should be avoided in order to minimize possible CNS excitation.

Route of Administration: Respiratory

In Vitro Use Guide

Effects of enflurane on NMDA, AMPA, and kainate-gated currents were examined in Xenopus laevis oocytes expressing mouse or human brain mRNA. Enflurane effects on the NMDA, kainate, or AMPA currents were obtained by a preincubation of enflurane alone for 60 s before a coapplication of various drugs and enflurane. Enflurane, at a clinically relevant concentration (1.8 mM), significantly inhibited both maximal and least measurable NMDA, kainate, and AMPA receptor-gated currents.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 17:29:39 GMT 2023` Edited by `admin` on `Fri Dec 15 17:29:39 GMT 2023`
Record UNII	91I69L5AY5
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ENFLURANE

Official Name

English

ENFLURANE [ORANGE BOOK]

Common Name

English

NSC-115944

Code

English

COMPOUND 347

Common Name

English

enflurane [INN]

Common Name

English

ENFLURANE [VANDF]

Common Name

English

ENFLURANE [MI]

Common Name

English

ETHER, 2-CHLORO-1,1,2-TRIFLUOROETHYL DIFLUOROMETHYL

Systematic Name

English

ANESTHETIC COMPOUND NO. 347

Code

English

ENFLURANE [MART.]

Common Name

English

ENFLURANE [USP IMPURITY]

Common Name

English

ETHRANE

Brand Name

English

ENFLURANE [USP-RS]

Common Name

English

(±)-2-CHLORO-1,1,2-TRIFLUOROETHYL DIFLUOROMETHYL ETHER

Systematic Name

English

ETHANE, 2-CHLORO-1-(DIFLUOROMETHOXY)-1,1,2-TRIFLUORO-

Systematic Name

English

ENFLURANE [GREEN BOOK]

Common Name

English

OHIO 347

Common Name

English

ENFLURANE [USAN]

Common Name

English

ALYRANE

Brand Name

English

Enflurane [WHO-DD]

Common Name

English

347

Code

English

ENFLURANE [JAN]

Common Name

English

ETHANE, 2-CHLORO-1-(DIFLUOROMETHOXY)-1,1,2-TRIFLUORO-, (±)-

Systematic Name

English

R-E-235CA2

Code

English

EFRANE

Brand Name

English

ENFLURANE [USP MONOGRAPH]

Common Name

English

METHYLFLURETHER

Common Name

English

2-CHLORO-1-(DIFLUOROMETHOXY)-1,1,2-TRIFLUOROETHANE

Systematic Name

English

Classification Tree Code System Code

NDF-RT

N0000175975